Amanta Healthcare’s ₹126 Crore IPO Set to Supercharge Sterile Product Expansion

Amanta Healthcare charges into public markets with ambitious ₹126 crore fundraising push.

Capacity Expansion Play

The capital injection targets sterile manufacturing infrastructure—because nothing says 'growth' like betting big on products that can't tolerate a single speck of dust. The move positions Amanta to capitalize on India's booming pharmaceutical sector while traditional investors still puzzle over whether healthcare stocks are actually tech plays in disguise.

Market Timing Masterstroke—Or Another IPO Cash Grab?

Launching amid peak healthcare sector optimism shows either brilliant timing or sheer opportunism. The sterile products segment promises margins that'd make even legacy pharma giants blush—assuming they can execute without contaminating the balance sheet along with their vials.

Because when your product requires absolute purity, why shouldn't your fundraising strategy embrace the opposite?

Timeline

The anchor portion will open on Friday and the issue will close on September 3.

Beeline Capital Advisors will be the lead Manager to the Issue while MUFG Intime India has been appointed as registrar.

Bhavesh Patel, Chairman and Managing Director, Amanta Healthcare said the company has grown by developing and supplying a wide range of sterile liquid products across therapeutic segments and medical devices both across domestic and international markets.

The IPO will facilitate the company to expand manufacturing capabilities with new SteriPort and SVP lines at Hariyala facility besides supporting future plans.

Financials

In FY25, the company achieved a revenue of ₹275 crore, EBITDA of ₹61 crore and net profit of ₹10 crore.

Published on August 25, 2025